Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

Sponsor
Bristol-Myers Squibb
Study ID
NCT07722507
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Antifibrotic therapy — DRUG
    As per product label prescribed by treating physician

Study Details

This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.

Key Dates

First listed
Jul 23, 2026
Start date
Aug 1, 2026
Status verified
Jul 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Continuation group
    Participants who have continued at least one antifibrotic therapy for a specific period (≥6 months) at the time of enrollment.
  • Arm: Discontinuation group
    Participants who have completely ceased all antifibrotic therapies for at least 1 month prior to enrollment.

Primary Outcome Measure

Participant reported decision-making process for antifibrotic therapy persistence or discontinuation when considering the impact of tolerability and adverse events collected via semi-structured qualitative participant interviews [ Time Frame: Day 1 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Related Studies